

# Peronne Joseph

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10891273/publications.pdf>

Version: 2024-02-01

9  
papers

524  
citations

1478505

6  
h-index

1588992

8  
g-index

10  
all docs

10  
docs citations

10  
times ranked

1200  
citing authors

#	ARTICLE	IF	CITATIONS
1	The miRâ€“181aâ€“SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer. <i>Cancer Research</i> , 2021, 81, 2044-2055.	0.9	21
2	A miRNA-Mediated Approach to Dissect the Complexity of Tumor-Initiating Cell Function and Identify miRNA-Targeting Drugs. <i>Stem Cell Reports</i> , 2019, 12, 122-134.	4.8	8
3	Host and Tumor Factor XII Drive Ovarian Cancer Maintenance and Progression. <i>Blood</i> , 2019, 134, 2384-2384.	1.4	2
4	Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 4588-4601.	7.0	11
5	Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 525-532.	1.4	7
6	miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer. <i>Biomarkers in Medicine</i> , 2015, 9, 241-257.	1.4	26
7	Critical role of Wnt/ $\beta$ -catenin signaling in driving epithelial ovarian cancer platinum resistance. <i>Oncotarget</i> , 2015, 6, 23720-23734.	1.8	158
8	microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelialâ€“mesenchymal transition. <i>Nature Communications</i> , 2014, 5, 2977.	12.8	226
9	Altered glutamine metabolism in platinum resistant ovarian cancer. <i>Oncotarget</i> , 0, 7, 41637-41649.	1.8	65